165 related articles for article (PubMed ID: 17119928)
1. CNS drugs approved by the centralised European procedure: true innovation or dangerous stagnation?
Barbui C; Cipriani A; Lintas C; Bertelé V; Garattini S
Psychopharmacology (Berl); 2007 Feb; 190(2):265-8. PubMed ID: 17119928
[No Abstract] [Full Text] [Related]
2. Reforming the EU environment for clinical trials: what are the challenges?
Fears R; Blum HE; Kelleher D; Meunier F; Souhami R
QJM; 2013 Sep; 106(9):787-9. PubMed ID: 23893498
[No Abstract] [Full Text] [Related]
3. Challenges and opportunities in bringing new medications to market for pediatric patients.
Upadhyaya HP; Gault L; Allen AJ
J Am Acad Child Adolesc Psychiatry; 2009 Nov; 48(11):1056-1059. PubMed ID: 19855220
[No Abstract] [Full Text] [Related]
4. [The effects of the 12th and 14th amendments to the AMG (Medical Preparations Act) on paediatric pharmaceutical research--a survey of the new regulations].
Kölch M; Lippert HD; Fegert JM
Z Kinder Jugendpsychiatr Psychother; 2006 Mar; 34(2):117-26. PubMed ID: 16610597
[TBL] [Abstract][Full Text] [Related]
5. [The significance of the list of prescribable drugs (so-called positive list) for psychopharmacotherapy].
Fritze J; Schmauss M; Holsboer F;
Nervenarzt; 2003 Feb; 74(2):195-7. PubMed ID: 12683388
[No Abstract] [Full Text] [Related]
6. [GCP inspections of clinical trials].
Schwarz G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):181-8. PubMed ID: 15726459
[TBL] [Abstract][Full Text] [Related]
7. [Clinical trials in Germany and in the EU in the new legislative environment. An analysis from the industry's point of view].
Heidenreich K; Möritz A; Löffler H; Oberle-Rolle B
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):415-22. PubMed ID: 15830252
[TBL] [Abstract][Full Text] [Related]
8. [European network for investigation of medicinal products in children (Medichildren)].
Pons G
Arch Pediatr; 2006 Jun; 13(6):631. PubMed ID: 16713209
[No Abstract] [Full Text] [Related]
9. Pediatric psychopharmacological research in the post EU regulation 1901/2006 era.
Schmäl C; Becker K; Berg R; Brünger M; Lehmkuhl G; Oehler KU; Ruppert T; Staudter C; Trott GE; Dittmann RW
Z Kinder Jugendpsychiatr Psychother; 2014 Nov; 42(6):441-9. PubMed ID: 25335522
[TBL] [Abstract][Full Text] [Related]
10. [Fundamental principles of clinical trials].
Skarke C; Geisslinger G
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Apr; 48(4):401-7. PubMed ID: 15830250
[TBL] [Abstract][Full Text] [Related]
11. Regulatory policies on medicines for psychiatric disorders: is Europe on target?
Barbui C; Garattini S
Br J Psychiatry; 2007 Feb; 190():91-3. PubMed ID: 17267922
[TBL] [Abstract][Full Text] [Related]
12. [Clinical research. Effects of European legislation and current developments].
Sudhop T; Enzmann H; Klar R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Apr; 52(4):375-6. PubMed ID: 19343281
[No Abstract] [Full Text] [Related]
13. [Network for investigation of medicinal products in children].
Kassaï B; Treluyer JM; Jacqz-Aigrain E; Pons G
Arch Pediatr; 2006 Jun; 13(6):631-4. PubMed ID: 16697606
[No Abstract] [Full Text] [Related]
14. Regulating clinical trials in Europe.
Willmott G
Lancet Oncol; 2013 May; 14(6):453-4. PubMed ID: 23522922
[No Abstract] [Full Text] [Related]
15. [Quality requirements governing non-commercial clinical trials within the framework of clinical drug development in humans in the EU. Challenges, opportunities, and questions experienced by treatment centres].
Boos J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2005 Feb; 48(2):196-203. PubMed ID: 15726461
[TBL] [Abstract][Full Text] [Related]
16. Germany opposes EU plans for regulating clinical trials owing to lack of ethical standards.
Tuffs A
BMJ; 2012 Oct; 345():e6640. PubMed ID: 23033377
[No Abstract] [Full Text] [Related]
17. [The authorization of clinical trials by the federal authorities].
Schriever J; Schwarz G; Steffen C; Krafft H
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2009 Apr; 52(4):377-86. PubMed ID: 19266174
[TBL] [Abstract][Full Text] [Related]
18. To which extent should potency choice in homeopathy be "regulated": has European legislation gone too far?
van Haselen R
Wien Med Wochenschr; 2005 Nov; 155(21-22):479-81. PubMed ID: 16425107
[TBL] [Abstract][Full Text] [Related]
19. Premarketing trials: too few patients.
Prescrire Int; 2014 Oct; 23(153):251. PubMed ID: 25964980
[No Abstract] [Full Text] [Related]
20. The need for ibogaine in drug and alcohol addiction treatment.
Donnelly JR
J Leg Med; 2011 Jan; 32(1):93-114. PubMed ID: 21391058
[No Abstract] [Full Text] [Related]
[Next] [New Search]
